Tertile | p trend | ||||
---|---|---|---|---|---|
1 | 2 | 3 | |||
Estradiol | |||||
All women | Cases/controls | 68/137 | 70/134 | 82/133 | |
OR (95% CI) | Reference | 1.06 (0.69–1.63) | 1.29 (0.80–2.07) | 0.15 | |
ER+/PR+ | Cases/controls | 47/98 | 54/94 | 51/90 | |
OR (95% CI) | Reference | 1.16 (0.69–1.93) | 1.11 (0.62–1.97) | 0.60 | |
Free estradiol | |||||
All women | Cases/controls | 67/127 | 78/126 | 65/121 | |
OR (95% CI) | Reference | 1.14 (0.74–1.75) | 0.95 (0.59–1.54) | 0.86 | |
ER+/PR+ | Cases/controls | 48/90 | 54/83 | 41/85 | |
OR (95% CI) | Reference | 1.13 (0.68–1.90) | 0.81 (0.45–1.44) | 0.72 | |
Estrone | |||||
All women | Cases/controls | 63/138 | 81/137 | 78/135 | |
OR (95% CI) | Reference | 1.27 (0.85–1.91) | 1.25 (0.79–1.97) | 0.45 | |
ER+/PR+ | Cases/controls | 47/97 | 60/96 | 47/93 | |
OR (95% CI) | Reference | 1.25 (0.77–2.02) | 0.96 (0.55–1.65) | 0.79 | |
Testosterone | |||||
All women | Cases/controls | 30/137 | 77/136 | 84/134 | |
OR (95% CI) | Reference | 1.29 (0.84–1.96) | 1.46 (0.96–2.21) | 0.04 | |
ER+/PR+ | Cases/controls | 36/99 | 57/95 | 60/89 | |
OR (95% CI) | Reference | 1.69 (1.00–2.86) | 1.94 (1.16–3.25) | 0.01 | |
Free testosterone | |||||
All women | Cases/controls | 73/128 | 57/127 | 81/122 | |
OR (95% CI) | Reference | 0.81 (0.52–1.25) | 1.16 (0.73–1.83) | 0.47 | |
ER+/PR+ | Cases/controls | 44/97 | 41/79 | 59/84 | |
OR (95% CI) | Reference | 1.23 (0.72–2.12) | 1.68 (0.96–2.94) | 0.04 | |
Progesterone | |||||
All women | Cases/controls | 74/138 | 80/134 | 67/134 | |
OR (95% CI) | Reference | 1.10 (0.72–1.68) | 0.89 (0.56–1.40) | 0.77 | |
ER+/PR+ | Cases/controls | 55/84 | 55/99 | 43/99 | |
OR (95% CI) | Reference | 0.75 (0.44–1.27) | 0.55 (0.31–0.99) | 0.05 | |
SHBG | |||||
All women | Cases/controls | 59/128 | 67/127 | 86/129 | |
OR (95% CI) | Reference | 1.21 (0.78–1.87) | 1.68 (1.05–2.70) | 0.13 | |
ER+/PR+ | Cases/controls | 44/85 | 46/83 | 55/96 | |
OR (95% CI) | Reference | 1.08 (0.64–1.83) | 1.18 (0.67–2.08) | 0.70 |